Skip to main content

stock

NBIX · NEUROCRINE BIOSCIENCES INC

What NEUROCRINE BIOSCIENCES INC reports to the SEC, read from its filings.

Open in the app

Price

The live NBIX price and today's change.

Sign in to see this

Chart

Thirty days of daily bars, with signal levels drawn on them.

Sign in to see this

Signals

The latest signal group Nakagai's scanner recorded on NBIX.

Sign in to see this

Options positioning

Gamma exposure levels from the options market.

Sign in to see this

Technicals

Trend, momentum and volatility gauges per timeframe.

Sign in to see this

What it is

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Filer (SEC EDGAR)
EDGAR filing index
Shares outstanding
101,649,181 as of 2026-07-22 (XBRL frame CY2026Q2I)

Key stats

Valuation

P/E
Locked
P/S
Locked
P/B
Locked
Enterprise value
Locked
EV/EBIT
Locked
FCF yield
Locked

Margins

Gross
—
Operating
23.6%
Net
20.9%

Returns

ROE
19.1%
ROA
13.2%

Health

Current ratio
1.9x
Debt/equity
—

Deep value

NCAV
-$28.00M
NCAV per share
-$0.28
Price/NCAV
Locked
NNWC
-$615.75M
NNWC per share
-$6.06
Price/NNWC
Locked

Valuation and the price multiples are built on the live price. Trailing twelve months to 2026-06-30; balance sheet at 2026-06-30.

Sign in to see this

Debt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.

Results

Period endRevenueGross profit (not reported by this company)Operating incomeNet incomeFiling
2026-06-30$959.00M—Gross profit: unreported by this company.$151.50M$144.40M
10-Q filed 2026-07-31
2026-03-31$814.50M—Gross profit: unreported by this company.$193.40M$197.90M
10-Q filed 2026-05-05
2025-12-31$805.50M—Gross profit: unreported by this company.$210.90M$153.70M
DEF 14A filed 2026-04-15
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
Assembled from more than one filing; the filing above is only the newest of them.
2025-09-30$794.90M—Gross profit: unreported by this company.$239.00M$209.50M
10-Q filed 2025-10-28
2025-06-30$687.50M—Gross profit: unreported by this company.$145.60M$107.50M
10-Q filed 2026-07-31
2025-03-31$572.60M—Gross profit: unreported by this company.$23.60M$7.90M
10-Q filed 2026-05-05
2024-12-31$627.70M—Gross profit: unreported by this company.$142.00M$103.10M
DEF 14A filed 2026-04-15
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
Assembled from more than one filing; the filing above is only the newest of them.
2024-09-30$622.10M—Gross profit: unreported by this company.$183.80M$129.80M
10-Q filed 2025-10-28
Assets
$5.36B
Equity
$3.69B

Balance as of 2026-06-30.

Ten years

Fiscal year endRevenueOperating incomeNet incomeFree cash flow
2025-12-31$2.86B$619.10M$478.60M$748.70M
2024-12-31$2.36B$570.50M$341.30M$557.20M
2023-12-31$1.89B$250.90M$249.70M$361.60M
2022-12-31$1.49B$249.00M$154.50M$322.90M
2021-12-31$1.13B$102.50M$89.60M$233.10M
2020-12-31$1.05B$163.00M$407.30M$217.60M
2019-12-31$788.10M$72.30M$37.00M$132.30M
2018-12-31$451.20M$36.80M$21.10M$76.60M
2017-12-31$161.63M-$131.36M-$142.54M-$101.27M
2016-12-31$15.00M-$147.37M-$141.09M-$110.29M

Company filings

Insiders, politicians and funds

Insider trades, last 90 days

Politician trades, last 90 days

No politician trades filed in the last 90 days.

Funds

News

Stories that named NBIX, and the market events around them.

Sign in to see this

Board

The NBIX board could not be loaded.

Retry the NBIX board

nakagai

Signals on NBIX come from a rule, not a model.

Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.

Members post on the NBIX board

This page is not financial advice. Trade at your own judgment and risk. Read the terms that govern posting here.

NEUROCRINE BIOSCIENCES INC (NBIX): SEC filings, financials and insider trades · Nakagai